Published in Biochem Biophys Res Commun on January 14, 2009
Cardiovascular biology of the incretin system. Endocr Rev (2012) 2.42
GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med (2013) 2.31
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig (2013) 1.55
Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes. Diabetes (2012) 1.18
The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther (2010) 1.12
Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. Am J Physiol Renal Physiol (2012) 1.03
Coming full circle in diabetes mellitus: from complications to initiation. Nat Rev Endocrinol (2013) 1.01
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol (2012) 1.00
Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol (2012) 0.99
Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice. Hypertension (2012) 0.99
The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol (2010) 0.94
Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes (2013) 0.89
Clinical therapeutic strategies for early stage of diabetic kidney disease. World J Diabetes (2014) 0.83
The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol (2010) 0.82
Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats. PLoS One (2014) 0.81
DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury. Lab Invest (2016) 0.80
Pleiotropic effects of incretins. Indian J Endocrinol Metab (2012) 0.80
Direct cardiovascular effects of glucagon like peptide-1. Diabetol Metab Syndr (2013) 0.80
Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol (2014) 0.80
Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist. J Diabetes Investig (2016) 0.79
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials. J Diabetes Res (2015) 0.79
Cardiovascular and hemodynamic effects of glucagon-like peptide-1. Rev Endocr Metab Disord (2014) 0.78
A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes. Diabetes Ther (2012) 0.78
DPP4 deficiency preserved cardiac function in abdominal aortic banding rats. PLoS One (2014) 0.77
Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats. Hypertens Res (2015) 0.77
A Novel GLP1 Receptor Interacting Protein ATP6ap2 Regulates Insulin Secretion in Pancreatic Beta Cells. J Biol Chem (2015) 0.75
Suppression of ROS Production by Exendin-4 in PSC Attenuates the High Glucose-Induced Islet Fibrosis. PLoS One (2016) 0.75
Gastrointestinal-Renal Axis: Role in the Regulation of Blood Pressure. J Am Heart Assoc (2017) 0.75
Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet (2008) 9.39
SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet (2008) 8.63
The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev (2007) 6.79
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet (2009) 3.67
Regulation of intrarenal angiotensin II in hypertension. Hypertension (2002) 3.34
Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol Biol Cell (2009) 3.29
Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population. Diabetes (2007) 3.24
Urinary angiotensinogen as an indicator of intrarenal Angiotensin status in hypertension. Hypertension (2003) 2.99
Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest (2010) 2.92
Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension (2006) 2.89
A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nat Genet (2010) 2.81
Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol (2008) 2.74
Role of NAD(P)H oxidase- and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension (2005) 2.67
Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol (2012) 2.58
Zscan4 regulates telomere elongation and genomic stability in ES cells. Nature (2010) 2.46
The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase. J Biol Chem (2008) 2.40
Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc (2013) 2.30
Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol (2005) 2.30
Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol (2005) 2.25
Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest (2004) 2.24
Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how? Nephrol Dial Transplant (2008) 2.21
Comparison of HOMA-IR, HOMA-β% and disposition index between US white men and Japanese men in Japan: the ERA JUMP study. Diabetologia (2014) 2.21
Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes (2005) 2.12
Comparison of central blood pressure and cardio-ankle vascular index for association with cardiac function in treated hypertensive patients. Hypertens Res (2009) 2.07
Regression of nephropathy developed in diabetes by (Pro)renin receptor blockade. J Am Soc Nephrol (2007) 2.04
SIRT1 and insulin resistance. Nat Rev Endocrinol (2009) 1.96
Replication of genome-wide association studies of type 2 diabetes susceptibility in Japan. J Clin Endocrinol Metab (2008) 1.91
Less subclinical atherosclerosis in Japanese men in Japan than in White men in the United States in the post-World War II birth cohort. Am J Epidemiol (2007) 1.90
Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension (2003) 1.89
Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol (2007) 1.87
Much lower prevalence of coronary calcium detected by electron-beam computed tomography among men aged 40-49 in Japan than in the US, despite a less favorable profile of major risk factors. Int J Epidemiol (2004) 1.86
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology (2004) 1.85
Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. EMBO J (2002) 1.82
SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J Biol Chem (2006) 1.81
Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol (2004) 1.75
Cerebral microvascular disease predicts renal failure in type 2 diabetes. J Am Soc Nephrol (2010) 1.72
Modulation of Valpha19 NKT cell immune responses by alpha-mannosyl ceramide derivatives consisting of a series of modified sphingosines. Eur J Immunol (2007) 1.68
Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol (2006) 1.67
Systemic cholesterol embolization syndrome associated with myeloperoxidase-anti-neutrophil cytoplasmic antibody. Intern Med (2006) 1.67
Enhanced sodium sensitivity and disturbed circadian rhythm of blood pressure in essential hypertension. J Hypertens (2006) 1.67
Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes (2011) 1.61
Complement 3 activates the renal renin-angiotensin system by induction of epithelial-to-mesenchymal transition of the nephrotubulus in mice. Am J Physiol Renal Physiol (2013) 1.59
Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade. J Hypertens (2006) 1.59
Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol (2007) 1.56
Familial pseudohyperkalemia: a rare cause of hyperkalemia. Intern Med (2005) 1.55
Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes (2005) 1.54
Abnormal angiogenesis in diabetic nephropathy. Diabetes (2009) 1.53
Systemic candesartan reduces brain angiotensin II via downregulation of brain renin-angiotensin system. Hypertens Res (2009) 1.51
Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo. Am J Physiol Endocrinol Metab (2008) 1.50
Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis. Clin Exp Nephrol (2003) 1.50
Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care (2007) 1.50
Diabetic neuropathy and nerve regeneration. Prog Neurobiol (2003) 1.49
Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am J Hum Genet (2004) 1.49
Multiphoton imaging of the glomerular permeability of angiotensinogen. J Am Soc Nephrol (2012) 1.48
Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation. Free Radic Biol Med (2006) 1.48